
By Marketwired . | Article Rating: |
|
August 21, 2014 09:30 AM EDT | Reads: |
566 |

HIGH BRIDGE, NJ -- (Marketwired) -- 08/21/14 -- MedEvoke, a Medisys Health Communications Company, and a premier provider of strategically aligned scientific narrative development for the biopharmaceutical industry, today announced their selection to the Inc. 500|5000 list, an exclusive ranking of the nation's fastest-growing privately held companies. With three-year revenue growth of approximately 200%, MedEvoke has tripled the number of clients since 2010, including at least one major new client every year. MedEvoke additionally ranked an impressive 4th among healthcare suppliers in New Jersey.
Anna Walz, CEO of MedEvoke noted, "We are very pleased to have achieved this milestone. In this industry, it is very challenging to realize significant growth, but MedEvoke has tapped into a significant need in the biopharmaceutical industry -- achieving global alignment in the development of singular evidence-based scientific narratives. MedEvoke's expertise and proprietary ISIS methodology have helped dozens of biopharmaceutical companies reconcile their competing strategies and objectives. We believe this has been fundamental in driving our success over the past five years."
According to recent estimates, the biopharmaceutical industry typically spends $4-6B annually on extraneous or unnecessary clinical endpoints. Achieving global alignment leads to more efficient, powerful trial design and the potential for stronger product labels. This is critical when considering the fact that only about 10% of products in development ultimately launch, and 90% of those launched products already have a competitor in late stage development.
MedEvoke currently supports most of the top 20 pharmaceutical companies, as well as numerous mid-size and emerging biotechnology companies. The company now shares a pedigree with other Inc. 500|5000 awardees including Microsoft, Timberland, Vizio, Intuit, Chobani, Oracle, and Zappos.com.
About MedEvoke
MedEvoke is a premier provider of globally aligned, evidence-based scientific narrative development for the biopharmaceutical industry. Leveraging its proven expertise and a simple, yet powerful methodology, MedEvoke ensures organizational alignment by reconciling a client's competing goals, objectives, languages, cultures and budgets across the many operational functions and regional affiliates. MedEvoke's approach mitigates the risks associated with duplicated effort, unclear direction and poor communications, allowing clients to gain a competitive advantage, even when faced with unexpected changes in personnel, clinical trial results, or competitive environment. Headquartered in High Bridge, NJ, MedEvoke holds certifications from WBENC, NMSDC, and SBA.
Contact:
John Walz
Chief Financial Officer
Phone: 908.638.5885
Website: www.medevoke.com
Published August 21, 2014 Reads 566
Copyright © 2014 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
![]() Mar. 12, 2017 05:00 PM EDT Reads: 2,941 |
By Yeshim Deniz ![]() Mar. 12, 2017 03:30 PM EDT Reads: 1,822 |
By Yeshim Deniz ![]() Mar. 12, 2017 01:45 PM EDT Reads: 2,373 |
By Elizabeth White ![]() Mar. 12, 2017 11:15 AM EDT Reads: 3,192 |
By Liz McMillan ![]() Mar. 12, 2017 11:00 AM EDT Reads: 2,548 |
By Liz McMillan ![]() Mar. 12, 2017 10:45 AM EDT Reads: 1,914 |
By Yeshim Deniz ![]() Mar. 12, 2017 09:30 AM EDT Reads: 2,445 |
By Yeshim Deniz ![]() Mar. 12, 2017 07:30 AM EDT Reads: 1,841 |
By Yeshim Deniz ![]() Mar. 12, 2017 06:00 AM EDT Reads: 1,775 |
By Liz McMillan ![]() Mar. 12, 2017 03:45 AM EDT Reads: 2,033 |
By Yeshim Deniz ![]() Mar. 12, 2017 01:45 AM EST Reads: 2,313 |
By Yeshim Deniz ![]() Mar. 12, 2017 12:30 AM EST Reads: 3,229 |
By Liz McMillan ![]() Mar. 12, 2017 12:00 AM EST Reads: 12,340 |
By Yeshim Deniz ![]() Mar. 11, 2017 11:45 PM EST Reads: 1,914 |
By Carmen Gonzalez ![]() Mar. 11, 2017 11:15 PM EST Reads: 3,010 |
By Yeshim Deniz ![]() Mar. 11, 2017 10:15 PM EST Reads: 1,459 |
By Liz McMillan ![]() Mar. 11, 2017 08:30 PM EST Reads: 3,306 |
By Carmen Gonzalez ![]() Mar. 11, 2017 08:15 PM EST Reads: 3,311 |
By Elizabeth White ![]() Mar. 11, 2017 05:45 PM EST Reads: 2,101 |
By Liz McMillan ![]() Mar. 11, 2017 03:00 PM EST Reads: 5,016 |